Skip to content
SPACListing
Browse
ScreenerFilingsMarketDeadlinesSponsorsBanksSectorsLearnPricingWatchlist
Liquidated

ARYA SCIENCES ACQUISITION CORP.

CIK 0001746037

Cash in trust

$148.7M

$148,698,960

Trust per share

Redemption value

IPO

Oct 2018

$143.8M raised

Combination deadline

Not disclosed

Filings on record

73

Latest Feb 14, 2022

Overview

ARYA SCIENCES ACQUISITION CORP. is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0001746037. It completed its initial public offering in Oct 2018, raising $143.8M in gross proceeds. The vehicle is sponsored by ARYA Sciences Holdings, a Islands exempted through ARYA Sciences Holdings, a Cayman Islands exempted limited. The mandate targets healthcare. Deadline lapsed without a deal; trust returned to public shareholders.

we intend to focus on industries that complement our management team's background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare related industries.
The mandate, as stated in the IPO prospectus

Reading the filings

Arithmetic on what ARYA SCIENCES ACQUISITION CORP. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.

  • Warrant coverage

    Each unit carried one-half of one warrant per unit. Warrants are dilution deferred: they cost the holder nothing until exercised, and they overhang the post-combination share count. Thinner coverage is generally a sign of a stronger book at pricing.

  • Sponsor record

    ARYA Sciences Holdings, a Islands exempted has launched 2 vehicles. Of the 2 that have resolved, 0 closed a combination and 2 liquidated, a 0% completion rate. A sponsor's record is not a forecast, but it does tell you whether the team has taken a deal across the line before.

  • Underwriting

    Jefferies led the offering. It has been named on 46 SPAC IPOs, book-running 44 of them, and 0% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.

SEC filing history

Free tier: filings older than 24 hours
  • SC 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001172661-22-000697

    Feb 14, 2022

    4y ago

    Open filing
  • SC 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001412741-21-000001

    Feb 16, 2021

    5y ago

    Open filing
  • SC 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001172661-21-000544

    Feb 16, 2021

    5y ago

    Open filing
  • SC 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000950142-21-000587

    Feb 16, 2021

    5y ago

    Open filing
  • SC 13G/A

    SC 13G/A

    Accession 0001580642-21-000683

    Feb 12, 2021

    5y ago

    Open filing
  • SC 13G/A

    13G FINAL ANNUAL FILING (ARYAU)

    Accession 0000053417-21-000026

    Feb 10, 2021

    5y ago

    Open filing
  • SC 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001137774-21-000018

    Feb 9, 2021

    5y ago

    Open filing
  • SC 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001623632-20-001420

    Aug 10, 2020

    6y ago

    Open filing
  • 15-12B

    Deregistration of securities

    Accession 0001193125-20-191606

    Jul 13, 2020

    6y ago

    Open filing
  • 4

    Statement of changes in beneficial ownership

    Accession 0000950123-20-006744

    Jul 6, 2020

    6y ago

    Open filing
  • 4

    Statement of changes in beneficial ownership

    Accession 0000899243-20-018576

    Jul 6, 2020

    6y ago

    Open filing
  • SC 13G/A

    SC 13G/A

    Accession 0001193125-20-188110

    Jul 6, 2020

    6y ago

    Open filing
  • 4

    Statement of changes in beneficial ownership

    Accession 0000899243-20-018573

    Jul 6, 2020

    6y ago

    Open filing
  • 4

    Statement of changes in beneficial ownership

    Accession 0000950123-20-006741

    Jul 6, 2020

    6y ago

    Open filing
  • 25-NSE

    Notification of delisting

    Accession 0001354457-20-000308

    Jul 1, 2020

    6y ago

    Open filing
  • 25-NSE

    Notification of delisting

    Accession 0001354457-20-000307

    Jul 1, 2020

    6y ago

    Open filing
  • 25-NSE

    Notification of delisting

    Accession 0001354457-20-000306

    Jul 1, 2020

    6y ago

    Open filing
  • 8-K

    Submission of matters to a vote of security holders; Other events

    Items 5.07, 8.01, 9.01 · Accession 0001193125-20-182624

    Jun 29, 2020

    6y ago

    Open filing
  • 8-K

    Other events

    Items 8.01, 9.01 · Accession 0001193125-20-174660

    Jun 22, 2020

    6y ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-20-174661

    Jun 22, 2020

    6y ago

    Open filing
  • DEFM14A

    Definitive merger proxy statement

    Accession 0001193125-20-165771

    Jun 10, 2020

    6y ago

    Open filing
  • SC 13G

    Beneficial ownership report (passive)

    Accession 0001104659-20-059370

    May 11, 2020

    6y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001193125-20-137589

    May 8, 2020

    6y ago

    Open filing
  • 10-K/A

    10-K/A

    Accession 0001193125-20-110791

    Apr 17, 2020

    6y ago

    Open filing
  • 8-K

    Regulation FD disclosure

    Item 7.01 · Accession 0001193125-20-109316

    Apr 16, 2020

    6y ago

    Open filing
  • 8-K

    Regulation FD disclosure; Other events

    Items 7.01, 8.01, 9.01 · Accession 0001193125-20-077338

    Mar 18, 2020

    6y ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-20-077339

    Mar 18, 2020

    6y ago

    Open filing
  • 8-K

    Entry into a material definitive agreement; Regulation FD disclosure

    Items 1.01, 7.01, 9.01 · Accession 0001193125-20-075542

    Mar 17, 2020

    6y ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-20-075543

    Mar 17, 2020

    6y ago

    Open filing
  • 10-K

    Annual report

    Accession 0001193125-20-065243

    Mar 6, 2020

    6y ago

    Open filing

ARYA SCIENCES ACQUISITION CORP.: questions answered

What is ARYA SCIENCES ACQUISITION CORP.?

ARYA SCIENCES ACQUISITION CORP. is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0001746037. It completed its initial public offering in Oct 2018, raising $143.8M in gross proceeds. The vehicle is sponsored by ARYA Sciences Holdings, a Islands exempted through ARYA Sciences Holdings, a Cayman Islands exempted limited. The mandate targets healthcare. Deadline lapsed without a deal; trust returned to public shareholders.

How much does ARYA SCIENCES ACQUISITION CORP. hold in trust?

Approximately $148,698,960, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.

When must ARYA SCIENCES ACQUISITION CORP. complete a merger?

No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.

What happens if ARYA SCIENCES ACQUISITION CORP. does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in ARYA SCIENCES ACQUISITION CORP., and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

Is the trust value the same as the share price for ARYA SCIENCES ACQUISITION CORP.?

No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.

How much dilution do ARYA SCIENCES ACQUISITION CORP.'s founder shares and warrants create?

Each unit also carried one-half of one warrant per unit, which is dilution deferred until exercise. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.

Who sponsors ARYA SCIENCES ACQUISITION CORP., and what is their track record?

ARYA Sciences Holdings, a Cayman Islands exempted limited is the sponsor entity, part of the ARYA Sciences Holdings, a Islands exempted franchise. That franchise has launched 2 vehicles in total, of which 0 closed a combination and 2 liquidated, a 0% completion rate on resolved vehicles. Named principals: Adam Stone, Joseph Edelman.

Which banks underwrote the ARYA SCIENCES ACQUISITION CORP. IPO?

Jefferies, Chardan. Jefferies and Chardan were credited as book-running managers on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.

Is ARYA SCIENCES ACQUISITION CORP. a good investment?

That is not a question this site answers. ARYA SCIENCES ACQUISITION CORP. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this ARYA SCIENCES ACQUISITION CORP. data come from?

Filings ARYA SCIENCES ACQUISITION CORP. submitted to the SEC under CIK 0001746037: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Sep 4, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.